6533b829fe1ef96bd12899ff
RESEARCH PRODUCT
First clinical uterus transplantation trial: a six-month report.
Janusz MarcickiewiczNiclas KvarnströmKlaus GrothMichael OlaussonCesar Diaz-garciaSaskia EklindMarkus GäbelPernilla Dahm-kählerRanda AkouriAnders EnskogJohan MölneCecilia LundmarkJan HolgerssonMats BrännströmAshraf HanafyLiza JohannessonAndreas Tzakissubject
InfertilityAdultGraft Rejectionmedicine.medical_specialtymedicine.drug_classUterusABO Blood-Group SystemCohort Studiesmedicine.arteryUterus transplantationMedicineHumansProspective StudiesUterine arterybusiness.industryUterusObstetrics and GynecologyPerioperativeMiddle Agedmedicine.diseaseSurgeryClinical trialTransplantationmedicine.anatomical_structureReproductive MedicineBlood Group IncompatibilityTissue TransplantationCorticosteroidFeasibility StudiesFemalebusinessInfertility FemaleImmunosuppressive AgentsFollow-Up Studiesdescription
Objective To report the 6-month results of the first clinical uterus transplantation (UTx) trial. This type of transplantation may become a treatment of absolute uterine-factor infertility (AUFI). Design Prospective observational study. Setting University hospital. Patient(s) Nine AUFI women and their live uterine donors, the majority being mothers. Intervention(s) Live-donor UTx and low-dose induction immunosuppression. Main Outcome Measure(s) Data from preoperative investigations, surgery and follow-up for 6 months. Result(s) Durations of donor and recipient surgery ranged from 10 to 13 hours and from 4 to 6 hours, respectively. No immediate perioperative complications occurred in any of the recipients. After 6 months, seven uteri remained viable with regular menses. Mild rejection episodes occurred in four of these patients. These rejection episodes were effectively reversed by corticosteroid boluses. The two graft losses were because of acute bilateral thrombotic uterine artery occlusions and persistent intrauterine infection. Conclusion(s) The results demonstrate the feasibility of live-donor UTx with a low-dose immunosuppressive protocol. Clinical trial registration number NCT01844362.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-01-20 | Fertility and sterility |